Harvard Bioscience (HBIO) Liabilities and Shareholders Equity (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $77.9 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 2.33% year-over-year to $77.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $316.1 million (down 32.26% YoY) and the FY2025 annual result came in at $80.1 million, down 36.77% from the prior year.
• Liabilities and Shareholders Equity slipped to $77.9 million in Q1 2026 per HBIO's latest filing, from $80.1 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $158.0 million in Q1 2022 and bottomed at $77.9 million in Q1 2026.
• The 5-year median for Liabilities and Shareholders Equity is $133.2 million (2024), against an average of $122.8 million.
• The widest annual swing landed in 2022, when Liabilities and Shareholders Equity climbed 4.49%; it then sank 40.57% in 2025.
• Tracing HBIO's Liabilities and Shareholders Equity over 5 years: stood at $145.4 million in 2022, then fell by 5.5% to $137.4 million in 2023, then declined by 7.81% to $126.6 million in 2024, then tumbled by 36.77% to $80.1 million in 2025, then fell by 2.66% to $77.9 million in 2026.
• Per Business Quant, the three latest HBIO Liabilities and Shareholders Equity figures stand at $77.9 million (Q1 2026), $80.1 million (Q4 2025), and $78.0 million (Q3 2025).

Peer Comparison